Research Papers

19 of 69 papers

CSV Excel
Quick filters: Open Data Open Code Pre-registered Funding Declared COI Declared Open Access Clear Filters
Using the pathogenic and nonpathogenic nonhuman primate model for studying non-AIDS comorbidities.
Pandrea I; Landay A; Wilson C; Stock J; Tracy R; Apetrei C.
Curr HIV/AIDS Rep (Unknown)
Published: 2015
2/6 Transparent
Funding Declared
Bioinformatics and HIV latency.
Ciuffi A; Mohammadi P; Golumbeanu M; di Iulio J; Telenti A.
Curr HIV/AIDS Rep (Unknown)
Published: 2015
2/6 Transparent
Funding Declared
Human immunodeficiency virus (HIV)-1 integration sites in viral latency.
Rezaei SD; Cameron PU.
Curr HIV/AIDS Rep (Unknown)
Published: 2015
2/6 Transparent
Funding Declared
Enhancing the benefits of antiretroviral therapy in Vietnam: towards ending AIDS.
Kato M; Long NH; Duong BD; Nhan do T; Nguyen TT; Hai NH; Giang le M; Hoa do M; Van NT; Suthar AB; Fontaine C; Nadol P; Lo YR; McConnell MS.
Curr HIV/AIDS Rep (Unknown)
Published: 2014
2/6 Transparent
Funding Declared
Epidemiological implications of HIV-hepatitis C co-infection in South and Southeast Asia.
Ye S; Pang L; Wang X; Liu Z.
Curr HIV/AIDS Rep (Unknown)
Published: 2014
2/6 Transparent
Funding Declared
Update on HIV in Western Europe.
Nakagawa F; Phillips AN; Lundgren JD.
Curr HIV/AIDS Rep (Unknown)
Published: 2014
1/6 Transparent
HIV and neurocognitive dysfunction.
Spudich S.
Curr HIV/AIDS Rep (Unknown)
Published: 2013
1/6 Transparent
Overview of the current state of the epidemic.
Hankins C.
Curr HIV/AIDS Rep (Unknown)
Published: 2013
1/6 Transparent
The search for host genetic factors of HIV/AIDS pathogenesis in the post-genome era: progress to date and new avenues f…
Aouizerat BE; Pearce CL; Miaskowski C.
Curr HIV/AIDS Rep (Unknown)
Published: 2011
2/6 Transparent
Funding Declared
HIV/HCV co-infection: pathogenesis, clinical complications, treatment, and new therapeutic technologies.
Operskalski EA; Kovacs A.
Curr HIV/AIDS Rep (Unknown)
Published: 2011
2/6 Transparent
Funding Declared
Pathogenesis of HIV in the central nervous system.
Valcour V; Sithinamsuwan P; Letendre S; Ances B.
Curr HIV/AIDS Rep (Unknown)
Published: 2011
1/6 Transparent
Alcohol and HIV disease progression: weighing the evidence.
Hahn JA; Samet JH.
Curr HIV/AIDS Rep (Unknown)
Published: 2010
1/6 Transparent
Pre-exposure prophylaxis state of the science: empirical analogies for research and implementation.
Golub SA; Operario D; Gorbach PM.
Curr HIV/AIDS Rep (Unknown)
Published: 2010
1/6 Transparent
The four Cs of HIV prevention with African Americans: crisis, condoms, culture, and community.
Williams JK; Wyatt GE; Wingood G.
Curr HIV/AIDS Rep (Unknown)
Published: 2010
2/6 Transparent
Funding Declared
Methadone, buprenorphine, and street drug interactions with antiretroviral medications.
Gruber VA; McCance-Katz EF.
Curr HIV/AIDS Rep (Unknown)
Published: 2010
2/6 Transparent
Funding Declared
When to start antiretroviral therapy.
Jain V; Deeks SG.
Curr HIV/AIDS Rep (Unknown)
Published: 2010
1/6 Transparent
Where the wild things are: pathogenesis of SIV infection in African nonhuman primate hosts.
Pandrea I; Apetrei C.
Curr HIV/AIDS Rep (Unknown)
Published: 2010
2/6 Transparent
Funding Declared
Use of nonhuman primate models to develop mucosal AIDS vaccines.
Genescà M; Miller CJ.
Curr HIV/AIDS Rep (Unknown)
Published: 2010
2/6 Transparent
Funding Declared
The potential of RNA interference-based therapies for viral infections.
Huang DD.
Curr HIV/AIDS Rep (Unknown)
Published: 2008